Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicin
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1757-2215
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicin ; volume:4 ; number:1 ; day:05 ; month:12 ; year:2011 ; pages:1-11 ; date:12.2011
Journal of ovarian research ; 4, Heft 1 (05.12.2011), 1-11, 12.2011
- Urheber
-
Sherman-Baust, Cheryl A.
Becker, Kevin G.
Wood III, William H.
Zhang, Yongqing
Morin, Patrice J.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/1757-2215-4-21
- URN
-
urn:nbn:de:101:1-2021082319294734799783
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:51 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Sherman-Baust, Cheryl A.
- Becker, Kevin G.
- Wood III, William H.
- Zhang, Yongqing
- Morin, Patrice J.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy
Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer
HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells
Doxorubicin-induced ovarian toxicity
Intraperitoneal cisplatin and doxorubicin as maintenance chemotherapy for unresectable ovarian cancer: a case report
The synergistic mechanisms of propofol with cisplatin or doxorubicin in human ovarian cancer cells
NIPEC with Single-Dose Intraperitoneal Cisplatin and Paclitaxel in Stage III Epithelial Ovarian Cancer
Neoadjuvant therapy of BRCA1-driven ovarian cancer by combination of cisplatin, mitomycin C and doxorubicin
Genetic polymorphisms and gene-dosage effect in ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy
A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells
No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/cisplatin
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy
Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer
HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells
Doxorubicin-induced ovarian toxicity
Intraperitoneal cisplatin and doxorubicin as maintenance chemotherapy for unresectable ovarian cancer: a case report
The synergistic mechanisms of propofol with cisplatin or doxorubicin in human ovarian cancer cells
NIPEC with Single-Dose Intraperitoneal Cisplatin and Paclitaxel in Stage III Epithelial Ovarian Cancer
Neoadjuvant therapy of BRCA1-driven ovarian cancer by combination of cisplatin, mitomycin C and doxorubicin
Genetic polymorphisms and gene-dosage effect in ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy
A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells
No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/cisplatin
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy
Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer
HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells
Doxorubicin-induced ovarian toxicity
Intraperitoneal cisplatin and doxorubicin as maintenance chemotherapy for unresectable ovarian cancer: a case report
The synergistic mechanisms of propofol with cisplatin or doxorubicin in human ovarian cancer cells
NIPEC with Single-Dose Intraperitoneal Cisplatin and Paclitaxel in Stage III Epithelial Ovarian Cancer
Neoadjuvant therapy of BRCA1-driven ovarian cancer by combination of cisplatin, mitomycin C and doxorubicin
Genetic polymorphisms and gene-dosage effect in ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy
A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells